Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.9B | $274M | $165M | $253M | 19.1% | -4.9% | -266.9% |
| 2024 | $2.0B | $-28M | $-99M | $185M | -13.0% | 0.9% | 64.0% |
| 2023 | $2.0B | $30M | $-60M | $104M | -7.1% | 1.1% | -191.1% |
| 2022 | $2.0B | $157M | $66M | $137M | 7.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,972.02 | 1,994.64 | 2,012.92 | 1,913.85 |
| Operating Revenue | - | 1,951.75 | 1,992.04 | 2,010.29 | 1,901.64 |
| Cost Of Revenue | - | 1,504.99 | 1,573.08 | 1,558.58 | 1,420.15 |
| Gross Profit | - | 467.03 | 421.56 | 454.34 | 493.70 |
| Operating Expense | - | 267.03 | 263.71 | 270.66 | 262.62 |
| Selling General And Administration | - | 231.40 | 227.54 | 238.44 | 240.79 |
| Total Expenses | - | 1,772.02 | 1,836.79 | 1,829.24 | 1,682.76 |
| Operating Income | - | 200 | 157.85 | 183.68 | 231.08 |
| Total Operating Income As Reported | - | 172.69 | 7.32 | -68.71 | 208.81 |
| EBITDA | - | 156.70 | 29.89 | -28.37 | 274.22 |
| Normalized EBITDA | - | 237.36 | 196.08 | 218.25 | 256.54 |
| EBIT | - | 121.06 | -6.28 | -60.60 | 252.40 |
| Interest Expense | - | 39.70 | 42.08 | 40.74 | 35.97 |
| Net Interest Income | - | -39.70 | -42.08 | -40.74 | -35.97 |
| Other Income Expense | - | -78.94 | -164.14 | -244.28 | 21.31 |
| Interest Expense Non Operating | - | 39.70 | 42.08 | 40.74 | 35.97 |
| Net Non Operating Interest Income Expense | - | -39.70 | -42.08 | -40.74 | -35.97 |
| Pretax Income | - | 81.37 | -48.36 | -101.34 | 216.43 |
| Tax Provision | - | 18.81 | 12.05 | -2.27 | 51.04 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -18.63 | -34.90 | -5.52 | 4.17 |
| Net Income Continuous Operations | - | 62.56 | -60.41 | -99.07 | 165.39 |
| Net Income From Continuing And Discontinued Operation | - | 66.33 | -60.41 | -99.07 | 165.39 |
| Net Income From Continuing Operation Net Minority Interest | - | 62.57 | -60.41 | -99.07 | 165.39 |
| Net Income | - | 66.33 | -60.41 | -99.07 | 165.39 |
| Net Income Common Stockholders | - | 66.33 | -60.41 | -99.07 | 165.39 |
| Net Income Including Noncontrolling Interests | - | 66.33 | -60.41 | -99.07 | 165.39 |
| Normalized Income | - | 124.59 | 70.88 | 142.03 | 151.88 |
| Diluted NI Availto Com Stockholders | - | 66.33 | -60.41 | -99.07 | 165.39 |
| Basic Average Shares | - | 82.95 | 84.02 | 85.87 | 84.08 |
| Diluted Average Shares | - | 84.12 | 84.02 | 85.87 | 85.27 |
| Reconciled Depreciation | - | 35.64 | 36.17 | 32.23 | 21.83 |
| Reconciled Cost Of Revenue | - | 1,504.99 | 1,573.08 | 1,558.58 | 1,420.15 |
| Total Unusual Items | - | -80.66 | -166.19 | -246.62 | 17.68 |
| Total Unusual Items Excluding Goodwill | - | -80.66 | -166.19 | -246.62 | 17.68 |
| Minority Interests | 0.03 | 0 | 0 | 0 | - |
| Net Income Discontinuous Operations | 22.95 | 3.77 | 0 | 0 | - |
| Special Income Charges | - | -84.33 | -170.53 | -252.39 | -1.37 |
| Gain On Sale Of Business | - | 0 | 0 | -9.70 | 20.91 |
| Other Special Charges | 14.53 | 57.02 | - | - | - |
| Write Off | - | 0 | 20 | 0 | 0 |
| Impairment Of Capital Assets | - | 0 | 148.31 | 178.44 | 0 |
| Restructuring And Mergern Acquisition | - | 27.31 | 2.22 | 64.26 | 22.27 |
| Gain On Sale Of Security | - | 3.67 | 4.34 | 5.77 | 19.05 |
| Depreciation Amortization Depletion Income Statement | - | 35.64 | 36.17 | 32.23 | 21.83 |
| Depreciation And Amortization In Income Statement | - | 35.64 | 36.17 | 32.23 | 21.83 |
| General And Administrative Expense | - | 231.40 | 227.54 | 238.44 | 240.79 |
| Other Gand A | - | 231.40 | 227.54 | 238.44 | 240.79 |
| Gain On Sale Of Ppe | 7.28 | 0 | 0 | - | - |
| Earnings From Equity Interest | - | 1.72 | 2.06 | 2.34 | 3.63 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Pediatrix Medical Group, Inc.this co. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Stoke Therapeutics, Inc. | STOK | $1.9B | -272.47 | 5.32 | -2.0% | -95.36 |
| Pulse Biosciences, Inc. | PLSE | $1.9B | -25.62 | 23.12 | -90.2% | -23.61 |
| Zymeworks Inc. | ZYME | $1.8B | -22.76 | 6.88 | -30.2% | -22.40 |
| Maravai LifeSciences Holdings, Inc. | MRVI |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.8B |
| -14.08 |
| 8.67 |
| -61.6% |
| -13.48 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL | $1.8B | 110.33 | 5.14 | 4.7% | 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Nuvation Bio Inc. | NUVB | $1.8B | -8.80 | 5.89 | -66.9% | -8.95 |
| Peer Median | - | -11.44 | 5.61 | -44.1% | -11.22 | |